Forums and Workshop (September 12) - ET (Eastern Time, GMT-05:00)
Forums and Workshop (September 12) - ET (Eastern Time, GMT-05:00)
(1 Hour)
Essential Guide to Intellectual Property in Life Sciences Transactions and Protecting Medicines
Building a Desirable Intellectual Property Estate to Support Business Transactions and Protect Medicine
- Overview of Model Patent Estate
- Platform Technologies
- Drug Substance and Methods of Use
- Formulations and Methods of Manufacture
- Drug Label Instructions & Information
- Biomarkers and Other Technologies
- Offensive IP / Defensive IP
Freedom to Operate
- Timing and Scope of Patent Landscape Analysis
- How to Handle FTO Issues
Leveraging Your IP in Life Sciences Transactions
- Pre-Diligence Preparations
- Self Audit – do self audit
Standard list of IP diligence questions – make sure have answers for same and copies of the standard documents that will be requested
IP ownership (employee/contractor/vendor agreements; MTA/SRA), prior art analysis, FTO analysis, gov’t grant money, etc.
- Secure Strategic IP
- Accelerate examination to secure key patents
- Point Person - designate a point person who has knowledge of the IP Estate, the Product, and the Business Strategy
- Construct the IP Narrative
- Succinct and specific explanation for how Company IP protects current product candidates
- Data Room – well organized data room that has all the usual documents that will be requested
- Track what information is being shared / avoid accidental disclosures and/or violation of any export controls
Join our exclusive, invite only, Medtech BD Leaders Forum—an unparalleled gathering of 10-12 top-tier BD leaders.
Our forum will include an open format giving opportunity for general group discussions, featuring case studies, which foster candid and open dialogue about industry trends, deal structuring, valuation, approaches to partnering and more, with your peers.
Come and connect with like-minded professionals, forge strategic alliances, and expand your professional network.
General Discussion (suggested topics to include but not limited to);
- Hearing from BD leaders in attendance on how their companies are structured
- Interaction with corporate BD vs. corporate M&A
- Dedicated investment funds vs non dedicated funds? What are the drawbacks?
- Insight on deal timelines (from getting a deal started to fruition)
- Real life transaction insights/ examples (no proprietary info)
- Approaches to partnering
- Experience working with startups (opportunities & challenges)
Our forum operates under 🔒 Chatham House Rule: Promoting a free-flowing exchange of ideas, the Chatham House Rule ensures a confidential and productive environment, encouraging open and honest discussions.
(1 Hour)
For companies, founders, and entrepreneurs considering entrance into the public markets, this session will focus on the “3 Ps” of going public – preparation, path, and post-transaction; and the different ways to go public in challenging markets. Are you and your board prepared? What path is most appropriate for you: traditional or an alternative ‘going public avenue. How can you best prepare for success post-transaction?
Preparing to be Public, An Organization-Wide Process
Going public is a transformative event for an organization that is complex, requires significant attention for executive management, involves the entire organization and carries high execution risk. Whether you go public via a direct listing IPO, a SPAC, or other reverse merger, the level of effort and the cost of preparation should not be underestimated. Beginning preparation early enables an organization to better manage both.
Your key takeaways:
- Considerations to prepare your organization for going public
- How to assess overall readiness
- How to identify organizational gaps to address